<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="spleen and liver of infected mice were observed and the" exact="viral" post="loads of PRV in brain, liver and lung were"/>
 <result pre="liver compared with their WT littermates after PRV challenge, while" exact="viral" post="loads of PRV in brain, liver and lung of"/>
 <result pre="in brain, liver and lung of TG mice were significantly" exact="lower" post="than that of WT mice. Conclusions PBD-2 could inhibit"/>
 <result pre="found that PBD-2 can attenuate proliferation of porcine reproductive and" exact="respiratory" post="syndrome virus (PRRSV) in MA-104 cells [8]. Molecular docking"/>
 <result pre="that PBD-2 can attenuate proliferation of porcine reproductive and respiratory" exact="syndrome" post="virus (PRRSV) in MA-104 cells [8]. Molecular docking evaluation"/>
 <result pre="from PBD-2 have the potential to be used to inhibit" exact="hepatitis" post="E virus by interacting with its capsid protein [14]."/>
 <result pre="enveloped double-stranded DNA herpesvirus, is the etiological pathogen of Aujeszky’s" exact="disease" post="causing meningoencephalitis and paravertebral ganglioneuritis in pigs [15]. The"/>
 <result pre="DNA herpesvirus, is the etiological pathogen of Aujeszky’s disease causing" exact="meningoencephalitis" post="and paravertebral ganglioneuritis in pigs [15]. The Bartha-k61 vaccine"/>
 <result pre="in China since late 2011 [17]. In China, with the" exact="infection" post="rate being 13.14% in 2016, it still requires more"/>
 <result pre="have been described previously. Some α-defensins with antiviral ability against" exact="herpes" post="simplex virus (HSV) infection were characterized, such as human"/>
 <result pre="Some α-defensins with antiviral ability against herpes simplex virus (HSV)" exact="infection" post="were characterized, such as human neutrophil peptide (HNP) 1–4,"/>
 <result pre="HBD-3 have been confirmed to inactivate HSV [20, 25, 26]." exact="Bovine" post="neutrophil β-defensin 3 has been found to show inhibitory"/>
 <result pre="3 has been found to show inhibitory activity against bovine" exact="herpes" post="virus 1 [27, 28]. Besides, HBD-2 has been reported"/>
 <result pre="1 [27, 28]. Besides, HBD-2 has been reported to inhibit" exact="varicella" post="zoster virus infection [29]. Retrocyclins 1 and 2 and"/>
 <result pre="[27, 28]. Besides, HBD-2 has been reported to inhibit varicella" exact="zoster" post="virus infection [29]. Retrocyclins 1 and 2 and rhesus"/>
 <result pre="28]. Besides, HBD-2 has been reported to inhibit varicella zoster" exact="virus infection" post="[29]. Retrocyclins 1 and 2 and rhesus θ defensin"/>
 <result pre="Besides, HBD-2 has been reported to inhibit varicella zoster virus" exact="infection" post="[29]. Retrocyclins 1 and 2 and rhesus θ defensin"/>
 <result pre="3 belonging to θ-defensins have been found to suppress HSV" exact="infection" post="[30, 31]. Therefore, the utilization of defensins as drugs"/>
 <result pre="for generation of disease-resistant animals may be useful to control" exact="virus infection." post="Although swine serves as the natural host and reservoir"/>
 <result pre="often utilized as a preferred model organism to study PRV" exact="infection" post="because of their susceptibility to PRV. In this study,"/>
 <result pre="preferred model organism to study PRV infection because of their" exact="susceptibility to" post="PRV. In this study, the effects of PBD-2 on"/>
 <result pre="PK-15 cells were maintained in Dulbecco’s Modified Eagle Medium (Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine"/>
 <result pre="MA, USA) supplemented with 10% fetal bovine serum (FBS) (Thermo" exact="Fisher" post="Scientific) in an atmosphere of 5% CO2 at 37 °C."/>
 <result pre="maintenance medium. After 48 h, cell culture supernatants were collected for" exact="viral" post="DNA isolation using a Quick-DNA/RNA Viral Kit (Zymo Research,"/>
 <result pre="supernatants were collected for viral DNA isolation using a Quick-DNA/RNA" exact="Viral" post="Kit (Zymo Research, Irvine, CA, USA). The resulting viral"/>
 <result pre="Quick-DNA/RNA Viral Kit (Zymo Research, Irvine, CA, USA). The resulting" exact="viral" post="DNA was subjected to real-time quantitative PCR (RT-qPCR) along"/>
 <result pre="corresponding Ct value. Mice grouping and viability test of PRV" exact="infection" post="C57/BL TG mice expressing PBD-2 were generated by our"/>
 <result pre="according to the manufacturer’s instructions. The PRV copies in the" exact="total" post="DNA of tissue samples were measured by RT-qPCR and"/>
 <result pre="Compared with PRV without pretreatment of PBD-2, significant reduction in" exact="viral" post="titer was observed when PRV was pre-incubated with 40 μg/mL"/>
 <result pre="to inoculate cells, the PRV copies were measured 2 days after" exact="infection" post="(n = 5). Data are presented as mean ± SD from three independent"/>
 <result pre="one tailed Student′s t-test Survival rate analysis of TG mice after" exact="infection" post="of PRV The antiviral effect of PBD-2 on the"/>
 <result pre="that TG mice expression PBD-2 were more resistant to PRV" exact="infection" post="than control mice. Fig. 2 Survival of transgenic mice"/>
 <result pre="mice (TG) expressing PBD-2 and wild-type (WT) mice after PRV" exact="infection" post="(n = 4 for each group). The mice were intraperitoneally injected"/>
 <result pre="TCID50/mL). This result represents three independent experiments with similar results" exact="Viral" post="loads in TG mice after PRV infection The PRV"/>
 <result pre="with similar results Viral loads in TG mice after PRV" exact="infection" post="The PRV genomic copy numbers were quantified in brain,"/>
 <result pre="TG and WT mice infected with PRV by RT-qPCR. PRV" exact="viral" post="loads in brain tissues of TG mice and WT"/>
 <result pre="higher than those in liver and lung tissues. However, PRV" exact="viral" post="loads in brain (P &amp;lt; .001), liver (P &amp;lt; .0001) and lung (P &amp;lt; .05)"/>
 <result pre="liver (P &amp;lt; .0001) and lung (P &amp;lt; .05) of TG mice were significantly" exact="lower" post="than that of WT mice (Fig. 3). Hence, PBD-2"/>
 <result pre="of WT mice (Fig. 3). Hence, PBD-2 could significantly depress" exact="viral" post="loads of PRV in different tissues. Fig. 3 Viral"/>
 <result pre="depress viral loads of PRV in different tissues. Fig. 3" exact="Viral" post="loads of PRV in tissue samples of mice infected"/>
 <result pre="of PRV in tissue samples of mice infected with PRV." exact="Total" post="DNA used to determine PRV copy numbers were obtained"/>
 <result pre="with Welch′ s correction Histopathological analysis of TG mice after" exact="infection" post="of PRV The pathological changes of WT mice and"/>
 <result pre="pathological changes of WT mice and TG mice after PRV" exact="infection" post="were also detected. Microglia nodules associated with neuronal degeneration"/>
 <result pre="after PRV infection were also detected. Microglia nodules associated with" exact="neuronal" post="degeneration and necrosis were observed in brain tissue of"/>
 <result pre="of represented TG mice Discussion The impact of PBD-2 on" exact="viral" post="pathogenicity has not been well examined experimentally yet. A"/>
 <result pre="in PK-15 cells while no significant effect was observed for" exact="lower" post="concentrations of PBD-2 (Fig. 1b). These indicate that a"/>
 <result pre="that a threshold concentration is required for PBD-2 to inhibit" exact="viral" post="proliferation. According to the survivability, detectable virus copies and"/>
 <result pre="changes, the TG mice displayed significantly increased resistance to PRV" exact="infection" post="compared with the WT mice. Therefore, the antiviral effect"/>
 <result pre="revealed that defensins can direct inactive enveloped viruses by disrupting" exact="viral" post="lipid bilayers [34]. In this study, PRV was preincubated"/>
 <result pre="have a direct virucidal effect on PRV by damaging the" exact="viral" post="envelopes. Besides, it may also affect PRV entry because"/>
 <result pre="because PBD-2 was still present during the whole process of" exact="viral" post="adsorption. Since PRV shared high structural and sequence similarity"/>
 <result pre="of block HSV binding by interacting with heparan sulfate, the" exact="primary" post="receptor for HSV binding, while HBD-3 with enhanced inhibitory"/>
 <result pre="heparan sulfate and gB [20]. HD-5 was able to prevent" exact="viral" post="adhesion and entry of HSV by binding to both"/>
 <result pre="rabbit NP-1 and HNP-1, -2, -3 inactivated HSV by preventing" exact="viral" post="entry [22, 31, 35]. Retrocyclin 2 prevented HSV binding,"/>
 <result pre="on glycoprotein B [31]. In general, these defensins prevent HSV" exact="infection" post="by blocking viral binding, penetration or both. Whether PBD-2"/>
 <result pre="[31]. In general, these defensins prevent HSV infection by blocking" exact="viral" post="binding, penetration or both. Whether PBD-2 is able to"/>
 <result pre="binding, penetration or both. Whether PBD-2 is able to block" exact="viral" post="binding and penetration by interacting with specific host membrane"/>
 <result pre="overexpressing pigs and PBD-2 TG mice showed enhanced resistance to" exact="bacterial infection" post="[10, 13]. In this study, we further verified that"/>
 <result pre="pigs and PBD-2 TG mice showed enhanced resistance to bacterial" exact="infection" post="[10, 13]. In this study, we further verified that"/>
 <result pre="further verified that PBD-2 TG mice displayed increased resistance to" exact="viral infection." post="Thus, PBD-2 can be a useful target to generate"/>
 <result pre="be a useful target to generate disease-resistant animals against both" exact="bacterial" post="and viral infections. PRV is an important pig pathogen"/>
 <result pre="useful target to generate disease-resistant animals against both bacterial and" exact="viral" post="infections. PRV is an important pig pathogen which is"/>
 <result pre="tissues. In transgenic mice infected with PRV, PBD-2 could reduce" exact="viral" post="loads and alleviated tissue lesions at different degrees in"/>
 <result pre="PRV and other viruses. Attempts at using β-defensins to control" exact="viral" post="diseases in vivo have been carried out. Expression of"/>
 <result pre="in fishes improved their resistance to spring viraemia of carp" exact="virus infection" post="[40]. Application of murine β-defensin 2 as a DNA"/>
 <result pre="fishes improved their resistance to spring viraemia of carp virus" exact="infection" post="[40]. Application of murine β-defensin 2 as a DNA"/>
 <result pre="2 as a DNA vaccine adjuvant protected mice against H5N1" exact="avian influenza" post="viruses [41]. In addition, mice intranasally or intratracheally inoculated"/>
 <result pre="P9, a derivative of mouse β-defensin 4, were protected from" exact="infections" post="of three types of influenza A viruses and SARS-associated"/>
 <result pre="3 (rMBD3) in mice was found to alleviate coxsackievirus B3-induced" exact="myocarditis" post="[43]. Similarly, intravenous injection of rMBD3 improved the survival"/>
 <result pre="PBD-2 in vitro and in vivo were confirmed using PRV" exact="infection" post="model. The technique of large-scale production of PBD-2 [45]"/>
 <result pre="of PBD-2 as novel prophylactic and therapeutic methods against Aujeszky’s" exact="disease" post="and other viral diseases. In addition, it is worthy"/>
 <result pre="novel prophylactic and therapeutic methods against Aujeszky’s disease and other" exact="viral" post="diseases. In addition, it is worthy of further studies"/>
 <result pre="that they have no competing interest. References References 1.HollyMKDiazKSmithJGDefensins in" exact="viral infection" post="and pathogenesisAnnu Rev Virol2017436939110.1146/annurev-virology-101416-04173428715972 2.LehrerRIPrimate defensinsNat Rev Microbiol2004272773810.1038/nrmicro97615372083 3.SelstedMEOuelletteAJMammalian"/>
 <result pre="they have no competing interest. References References 1.HollyMKDiazKSmithJGDefensins in viral" exact="infection" post="and pathogenesisAnnu Rev Virol2017436939110.1146/annurev-virology-101416-04173428715972 2.LehrerRIPrimate defensinsNat Rev Microbiol2004272773810.1038/nrmicro97615372083 3.SelstedMEOuelletteAJMammalian"/>
 <result pre="al.Overexpression of porcine Beta-Defensin 2 enhances resistance to Actinobacillus pleuropneumoniae" exact="infection" post="in pigsInfect Immun2015832836284310.1128/IAI.03101-1425916992 11.HanFZhangHXiaXXiongHSongDZongXWangYPorcine beta-defensin 2 attenuates inflammation and"/>
 <result pre="Escherichia coliAnim Sci J2016871258126610.1111/asj.1254026707031 13.HuangCYangXHuangJLiuXYangXJinHHuangQLiLZhouRPorcine Beta-Defensin 2 provides protection against" exact="bacterial infection" post="by a direct bactericidal activity and alleviates inflammation via"/>
 <result pre="coliAnim Sci J2016871258126610.1111/asj.1254026707031 13.HuangCYangXHuangJLiuXYangXJinHHuangQLiLZhouRPorcine Beta-Defensin 2 provides protection against bacterial" exact="infection" post="by a direct bactericidal activity and alleviates inflammation via"/>
 <result pre="derivatives from bacteriocins and porcine beta defensin-2 as inhibitors of" exact="hepatitis" post="E virus capsid proteinVirusdisease20172828128810.1007/s13337-017-0383-729291214 15.MettenleiterTCBWJMMHVVRPseudorabies Virus. In Encyclopedia of"/>
 <result pre="defensinsJ Virol1986601068107410.1128/JVI.60.3.1068-1074.19863023659 20.HazratiEGalenBLuWWangWOuyangYKellerMJLehrerRIHeroldBCHuman alpha- and beta-defensins block multiple steps in" exact="herpes" post="simplex virus infectionJ Immunol20061778658866610.4049/jimmunol.177.12.865817142766 21.LehrerRIJungGRuchalaPAndreSGabiusHJLuWMultivalent binding of carbohydrates by"/>
 <result pre="a rabbit alpha-defensin, prevents the entry and intercellular spread of" exact="herpes" post="simplex virus type 2Antimicrob Agents Chemother20034749450010.1128/AAC.47.2.494-500.200312543649 23.WangAChenFWangYShenMXuYHuJWangSGengFWangCRanXet al.Enhancement of"/>
 <result pre="23.WangAChenFWangYShenMXuYHuJWangSGengFWangCRanXet al.Enhancement of antiviral activity of human alpha-defensin 5 against" exact="herpes" post="simplex virus 2 by arginine mutagenesis at adaptive evolution"/>
 <result pre="at adaptive evolution sitesJ Virol2013872835284510.1128/JVI.02209-1223269800 24.YasinBPangMTurnerJSChoYDinhNNWaringAJLehrerRIWagarEAEvaluation of the inactivation of" exact="infectious" post="herpes simplex virus by host-defense peptidesEur J Clin Microbiol"/>
 <result pre="adaptive evolution sitesJ Virol2013872835284510.1128/JVI.02209-1223269800 24.YasinBPangMTurnerJSChoYDinhNNWaringAJLehrerRIWagarEAEvaluation of the inactivation of infectious" exact="herpes" post="simplex virus by host-defense peptidesEur J Clin Microbiol Infect"/>
 <result pre="Vaccine Immunol201522799010.1128/CVI.00476-1425378352 29.CrackLRJonesLMalavigeGNPatelVOggGSHuman antimicrobial peptides LL-37 and human beta-defensin-2 reduce" exact="viral" post="replication in keratinocytes infected with varicella zoster virusClin Exp"/>
 <result pre="and human beta-defensin-2 reduce viral replication in keratinocytes infected with" exact="varicella" post="zoster virusClin Exp Dermatol20123753454310.1111/j.1365-2230.2012.04305.x22639919 30.BrandtCRAkkarawongsaRAltmannSJoseGKolbAWWaringAJLehrerRIEvaluation of a theta-defensin in"/>
 <result pre="human beta-defensin-2 reduce viral replication in keratinocytes infected with varicella" exact="zoster" post="virusClin Exp Dermatol20123753454310.1111/j.1365-2230.2012.04305.x22639919 30.BrandtCRAkkarawongsaRAltmannSJoseGKolbAWWaringAJLehrerRIEvaluation of a theta-defensin in a"/>
 <result pre="Dermatol20123753454310.1111/j.1365-2230.2012.04305.x22639919 30.BrandtCRAkkarawongsaRAltmannSJoseGKolbAWWaringAJLehrerRIEvaluation of a theta-defensin in a murine model of" exact="herpes" post="simplex virus type 1 keratitisInvest Ophthalmol Vis Sci2007485118512410.1167/iovs.07-030217962464 31.YasinBWangWPangMCheshenkoNHongTWaringAJHeroldBCWagarEALehrerRITheta"/>
 <result pre="a theta-defensin in a murine model of herpes simplex virus" exact="type 1" post="keratitisInvest Ophthalmol Vis Sci2007485118512410.1167/iovs.07-030217962464 31.YasinBWangWPangMCheshenkoNHongTWaringAJHeroldBCWagarEALehrerRITheta defensins protect cells from"/>
 <result pre="1 keratitisInvest Ophthalmol Vis Sci2007485118512410.1167/iovs.07-030217962464 31.YasinBWangWPangMCheshenkoNHongTWaringAJHeroldBCWagarEALehrerRITheta defensins protect cells from" exact="infection" post="by herpes simplex virus by inhibiting viral adhesion and"/>
 <result pre="Ophthalmol Vis Sci2007485118512410.1167/iovs.07-030217962464 31.YasinBWangWPangMCheshenkoNHongTWaringAJHeroldBCWagarEALehrerRITheta defensins protect cells from infection by" exact="herpes" post="simplex virus by inhibiting viral adhesion and entryJ Virol2004785147515610.1128/JVI.78.10.5147-5156.200415113897"/>
 <result pre="protect cells from infection by herpes simplex virus by inhibiting" exact="viral" post="adhesion and entryJ Virol2004785147515610.1128/JVI.78.10.5147-5156.200415113897 32.ChenHFangLHeQJinMSuoXWuMStudy on the isolation and"/>
 <result pre="Mol Biol20134254965498010.1016/j.jmb.2013.09.03824095897 35.JohnMKellerMJFamEHCheshenkoNHogartyKKasowitzAWallensteinSCarlucciMJTuyamaACLuWet al.Cervicovaginal secretions contribute to innate resistance to" exact="herpes" post="simplex virus infectionJ Infect Dis20051921731174010.1086/49716816235171 36.ChenJQiSGuoRYuBChenDDifferent messenger RNA expression"/>
 <result pre="immunomodulatory properties, the zebrafish β-defensin 2 (zfBD2) is a potent" exact="viral" post="DNA vaccine molecular adjuvantAntivir Res201410113614710.1016/j.antiviral.2013.11.00924286781 41.VemulaSVAmenOKatzJMDonisRSambharaSMittalSKBeta-defensin 2 enhances immunogenicity"/>
 <result pre="novel peptide with potent and broad-spectrum antiviral activities against multiple" exact="respiratory" post="virusesSci Rep201662200810.1038/srep2200826911565 43.JiangYZhuRLuoLMuQZhuYLuoHZouXShenXRecombinant mouse β-Defensin 3 protects against Coxsackievirus"/>
 <result pre="virusesSci Rep201662200810.1038/srep2200826911565 43.JiangYZhuRLuoLMuQZhuYLuoHZouXShenXRecombinant mouse β-Defensin 3 protects against Coxsackievirus B3-induced" exact="myocarditis" post="in miceIntervirology20155834334910.1159/00044258826829552 44.JiangYYangDLiWWangBJiangZLiMAntiviral activity of recombinant mouse β-defensin 3"/>
</results>
